Tags

Type your tag names separated by a space and hit enter

The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
Aliment Pharmacol Ther. 2004 Jun 15; 19(12):1255-60.AP

Abstract

BACKGROUND

The length of Barrett's oesophagus seems to correlate well with indicators of severe gastro-oesophageal reflux disease. However, it remains unknown whether prior acid suppressive therapy affects the length of newly diagnosed Barrett's oesophagus.

METHODS

A retrospective analysis of a well-characterized large cohort of patients with Barrett's oesophagus diagnosed between 1981 and 2000.

AIM

To compare the length of Barrett's oesophagus between patients who received acid suppressive therapy prior to their diagnosis to those who did not receive such therapy. Pharmacy records were obtained from Department of the Veterans Affairs computerized records and prospectively collected research records. We further examined the association between prior use of acid suppressive therapy and the length of Barrett's oesophagus in correlation analyses, as well as multivariate linear regression analyses while adjusting for differences in year of diagnosis, age, gender, ethnicity, and the presence of intestinal metaplasia of the gastric cardia. Results : There were 340 patients with Barrett's oesophagus first diagnosed between 1981 and 2000. The average length of Barrett's oesophagus at the time of first diagnosis was 4.4 cm (range: 0.5-16). Of all patients, 139 (41%) had prior use of histamine-2 receptor antagonists, or proton-pump inhibitors (41 used both), and 201 (59%) used neither prior to the diagnosis of Barrett's oesophagus. The mean length of Barrett's oesophagus was significantly shorter in patients with prior use of proton-pump inhibitors (3.4 cm) or proton-pump inhibitors and histamine-2 receptor antagonists (3.1 cm) when compared to those with none of these medications (4.8 cm). In the multivariate linear regression model, the prior use of proton-pump inhibitors or either proton-pump inhibitors or histamine-2 receptor antagonists was an independent predictor of shorter length of Barrett's oesophagus (P = 0.0396).

CONCLUSIONS

The use of acid suppressive therapy among patients is associated with a reduction in the eventual length of newly diagnosed Barrett's oesophagus with gastro-oesophageal reflux disease. This finding is independent of the year of diagnosis or demographic features of patients. Further studies are required to confirm this finding.

Authors+Show Affiliations

Section of Gastroenterology, The Houston, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA. hasheme@bcm.tmc.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

15191506

Citation

El-Serag, H B., et al. "The Length of Newly Diagnosed Barrett's Oesophagus and Prior Use of Acid Suppressive Therapy." Alimentary Pharmacology & Therapeutics, vol. 19, no. 12, 2004, pp. 1255-60.
El-Serag HB, Aguirre T, Kuebeler M, et al. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther. 2004;19(12):1255-60.
El-Serag, H. B., Aguirre, T., Kuebeler, M., & Sampliner, R. E. (2004). The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Alimentary Pharmacology & Therapeutics, 19(12), 1255-60.
El-Serag HB, et al. The Length of Newly Diagnosed Barrett's Oesophagus and Prior Use of Acid Suppressive Therapy. Aliment Pharmacol Ther. 2004 Jun 15;19(12):1255-60. PubMed PMID: 15191506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. AU - El-Serag,H B, AU - Aguirre,T, AU - Kuebeler,M, AU - Sampliner,R E, PY - 2004/6/12/pubmed PY - 2004/10/13/medline PY - 2004/6/12/entrez SP - 1255 EP - 60 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 19 IS - 12 N2 - BACKGROUND: The length of Barrett's oesophagus seems to correlate well with indicators of severe gastro-oesophageal reflux disease. However, it remains unknown whether prior acid suppressive therapy affects the length of newly diagnosed Barrett's oesophagus. METHODS: A retrospective analysis of a well-characterized large cohort of patients with Barrett's oesophagus diagnosed between 1981 and 2000. AIM: To compare the length of Barrett's oesophagus between patients who received acid suppressive therapy prior to their diagnosis to those who did not receive such therapy. Pharmacy records were obtained from Department of the Veterans Affairs computerized records and prospectively collected research records. We further examined the association between prior use of acid suppressive therapy and the length of Barrett's oesophagus in correlation analyses, as well as multivariate linear regression analyses while adjusting for differences in year of diagnosis, age, gender, ethnicity, and the presence of intestinal metaplasia of the gastric cardia. Results : There were 340 patients with Barrett's oesophagus first diagnosed between 1981 and 2000. The average length of Barrett's oesophagus at the time of first diagnosis was 4.4 cm (range: 0.5-16). Of all patients, 139 (41%) had prior use of histamine-2 receptor antagonists, or proton-pump inhibitors (41 used both), and 201 (59%) used neither prior to the diagnosis of Barrett's oesophagus. The mean length of Barrett's oesophagus was significantly shorter in patients with prior use of proton-pump inhibitors (3.4 cm) or proton-pump inhibitors and histamine-2 receptor antagonists (3.1 cm) when compared to those with none of these medications (4.8 cm). In the multivariate linear regression model, the prior use of proton-pump inhibitors or either proton-pump inhibitors or histamine-2 receptor antagonists was an independent predictor of shorter length of Barrett's oesophagus (P = 0.0396). CONCLUSIONS: The use of acid suppressive therapy among patients is associated with a reduction in the eventual length of newly diagnosed Barrett's oesophagus with gastro-oesophageal reflux disease. This finding is independent of the year of diagnosis or demographic features of patients. Further studies are required to confirm this finding. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/15191506/The_length_of_newly_diagnosed_Barrett's_oesophagus_and_prior_use_of_acid_suppressive_therapy_ L2 - https://doi.org/10.1111/j.1365-2036.2004.02006.x DB - PRIME DP - Unbound Medicine ER -